Literature DB >> 27793913

Ad-shWnt2b Vector Therapy Demonstrates Antitumor Activity in Orthotopic Intrapleural Models as Monitored with the In Vitro Imaging System (IVIS).

Masashi Kobayashi1, Cheng-Long Huang2, Makoto Sonobe2, Ryutaro Kikuchi2, Hiroshi Date2.   

Abstract

AIM: We investigated whether Wnt2B-inhibiting therapy has effective antitumor activity against Wnt2B-overexpressing cells in an orthotopic intrapleural model by monitoring with the in vitro imaging system (IVIS).
MATERIALS AND METHODS: Mice for the orthotopic intrapleural model were randomized into 3 groups (control, Ad-shWnt2B and Ad-scramble; 8 mice per group). The respective vector was injected into the intrapleural cavity of mice in the Ad-shWnt2B and Ad-scramble groups. After 6 weeks of vector treatment, all mice were monitored with the IVIS. Additionally, their body weight was measured until all mice died from the tumor or were sacrificed.
RESULTS: A549-Luc-positive cells showed cytotoxicity following exposure to the Ad-shWnt2B vector. The percentage of viable cells was significantly lower in A549-Luc cells treated with Ad-shWnt2B than with Ad-scramble (p<0.01 versus control or Ad-scramble, respectively). Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  A549; IVIS; Wnt2b; adenoviral vector; luciferase; orthotopic model

Mesh:

Substances:

Year:  2016        PMID: 27793913     DOI: 10.21873/anticanres.11175

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Molecular genetics and targeted therapy of WNT-related human diseases (Review).

Authors:  Masuko Katoh; Masaru Katoh
Journal:  Int J Mol Med       Date:  2017-07-19       Impact factor: 4.101

2.  Wnt2b and Wnt5a expression is highly associated with M2 TAMs in non‑small cell lung cancer.

Authors:  Ryota Sumitomo; Cheng-Long Huang; Hidenori Ando; Tatsuhiro Ishida; Hiroyuki Cho; Hiroshi Date
Journal:  Oncol Rep       Date:  2022-09-14       Impact factor: 4.136

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.